• Home
  • About Us
  • Our History

Our History

2006

Ace Vision Group, Inc.(AVG) was established in 2006 as a medical device company developing eye laser technology and natural therapeutic procedures to treat age-related eye dysfunction.

Read More >>

2007

AVG establishes Taiwan partnership with Vision ReNu Taiwan Corporation for R&D, clinical trials and development of the company's technology including manufacturing of surgical...

Read More >>

2008

AVG in collaboration with Vision ReNu and Emergo Group Jytong successfully complete regulatory submissions to both Taiwan FDA and China FDA approval for its laser and procedure.

Read More >>

2010

AVG selects the Chang Gung Memorial Hospital in Taipei, Taiwan as its Institutional partner to conduct the world's first LaserACE® procedure IRB registered clinical trials.

Read More >>

2011

AVG receives Taiwan FDA approval in October of 2011 and China FDA approval in December of 2011. Vision ReNu becomes significant shareholder in Ace Vision Group. AVG raised $2.1M through Taiwan...

Read More >>

2012

AVG launches its first IRB registered Clinical Trial in Taipei Taiwan in March of 2012 and first LaserACE® procedure in the world is performed by Dr. David HK Ma, MD, PhD in March 2012.

Read More >>

2013

AVG completes its enrolment of the Taiwan clinical trial and presents its 1 year data at major ophthalmology world congresses.

Read More >>

2014

AVG files an uber patent in March 2014 on behalf of its future technology device development efforts.

Read More >>

2015

AVG receives a $75,000 Grant from the SNEC to conduct its wound healing studies scheduled to begin in June of 2015.

Read More >>

 

Note: LaserACE® is not yet FDA approved or available in the United States. It is currently in clinical trials only in select areas outside of the United States.

logomobilesidebar